Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5–0.8 mg/kg for ≤12 cycles. With a med...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Burger, Jan A., Barr, Paul M., Robak, Tadeusz, Owen, Carolyn, Ghia, Paolo, Tedeschi, Alessandra, Bairey, Osnat, Hillmen, Peter, Coutre, Steven E., Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Simpson, David, Offner, Fritz, Moreno, Carol, Dai, Sandra, Lal, Indu, Dean, James P., Kipps, Thomas J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214263/
https://ncbi.nlm.nih.gov/pubmed/31628428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0602-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados